Apogee Q2 2026: $1.3B Cash, Pipeline Advances Ahead of AbbVie Vote
APGE has more than doubled off its 52-week low of $34.34.
Summary
Apogee Therapeutics reported Q2 2026 financial results with $1.3 billion in cash and a net loss of $85.9 million, while advancing its immunology pipeline ahead of the August 11 shareholder vote on AbbVie's $10.9 billion acquisition.
Key Events · Earnings and Guidance · APGE
-
Q2 2026 Financial Results
Cash, cash equivalents, and marketable securities totaled $1.3 billion as of June 30, 2026, up from $621.2 million a year earlier. The net loss reached $85.9 million, driven by higher R&D ($67.3M) and G&A ($24.3M) expenses, including $4.4 million in merger transaction costs.
-
Pipeline Advancements
A Phase 3 trial of zumilokibart in atopic dermatitis is planned for this year. The ELEVATE Phase 2a study in eosinophilic esophagitis is set to begin in the second half of 2026, and the ASPIRE Phase 2b trial in asthma will start in the first half of 2027. Interim data from the APG279 Phase 1b head-to-head study versus DUPIXENT are expected in the second half of 2026.
-
AbbVie Acquisition Context
These results arrive one day before the August 11, 2026 stockholder vote on AbbVie's $135.11 per share all-cash acquisition, valued at approximately $10.9 billion. The transaction is expected to close in the third quarter of 2026.
-
Strong Cash Runway
With $1.3 billion in cash and marketable securities, plus up to $1.3 billion in non-dilutive financing from Blackstone, Apogee is funded well beyond the acquisition close, eliminating near-term financing risk.
Analysis · APGE · Life Sciences
Ahead of tomorrow's stockholder vote on AbbVie's $135.11 per share all-cash acquisition, Apogee delivered Q2 2026 results that underscore its standalone strength. The company holds a robust $1.3 billion in cash, extending its runway well beyond the deal's expected close. R&D spending climbed to $67.3 million, reflecting the advancement of zumilokibart toward a Phase 3 trial in atopic dermatitis and the initiation of new studies in eosinophilic esophagitis and asthma. While the net loss widened to $85.9 million, the balance sheet remains solid. These figures provide shareholders with a final snapshot of value before the August 11 vote. Pipeline updates—including upcoming Phase 2 initiations and combination therapy data—highlight the portfolio's momentum, which AbbVie aims to capture.
How filings like this one have moved
In the 30 days to Oct 15, 2026, 29% of the 1483 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.47%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, APGE was trading at $134.79 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $10.2B. The 52-week trading range was $34.34 to $134.88. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.